<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04250155</url>
  </required_header>
  <id_info>
    <org_study_id>GO41596</org_study_id>
    <nct_id>NCT04250155</nct_id>
  </id_info>
  <brief_title>An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase Ia/Ib, Open-Label, Multicenter, Global, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XmAb24306 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, pharmacokinetics, and activity of
      XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with
      locally advanced or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of XmAb24306</measure>
    <time_frame>Baseline, then at pre-defined intervals for the first year of treatment or until participant discontinues study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR as Based on Radiographic Assessment by the Investigator Using Modified RECIST v1.1 for Immune-Based Therapeutics (iRECIST)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR as Based on Radiographic Assessment by the Investigator Using iRECIST</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS as Based on Radiographic Assessment by the Investigator Using iRECIST</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Phase 1a Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive XmAb24306 until study treatment discontinuation or study termination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1a Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive XmAb24306 until study treatment discontinuation or study termination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XmAb24306</intervention_name>
    <description>Participants will receive intravenous (IV) XmAb24306.</description>
    <arm_group_label>Phase 1a Dose Escalation</arm_group_label>
    <arm_group_label>Phase 1a Dose Expansion</arm_group_label>
    <other_name>RO7310729</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Participants will receive IV XmAb24306 followed by IV atezolizumab</description>
    <arm_group_label>Phase 1b Dose Escalation</arm_group_label>
    <arm_group_label>Phase 1b Dose Expansion</arm_group_label>
    <other_name>RO5541267</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XmAb24306</intervention_name>
    <description>Participants will receive IV XmAb24306 followed by IV atezolizumab.</description>
    <arm_group_label>Phase 1b Dose Escalation</arm_group_label>
    <arm_group_label>Phase 1b Dose Expansion</arm_group_label>
    <other_name>RO7310729</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key General Inclusion Criteria

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Life expectancy &gt;/= 12 weeks

          -  Adequate hematologic and end-organ function

          -  For participants receiving therapeutic anticoagulation: stable anticoagulant regimen

          -  Negative serum pregnancy test for women of childbearing potential

          -  Histologically confirmed locally advanced, recurrent, or metastatic incurable solid
             tumor malignancy

          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

          -  Availability of representative tumor specimens

        Key General Exclusion Criteria

          -  Pregnant or breastfeeding, or intending to become pregnant during the study

          -  Significant cardiovascular disease

          -  Current treatment with medications that prolong the QT interval

          -  Known clinically significant liver disease

          -  Poorly controlled Type 2 diabetes mellitus

          -  Symptomatic, untreated, or actively progressing CNS metastases

          -  History of leptomeningeal disease

          -  History of malignancy other than disease under study within 3 years prior to screening

          -  Active or history of autoimmune disease or immune deficiency

          -  Active tuberculosis, hepatitis B, hepatitis C, or known/suspected Epstein Barr virus
             infection

          -  Positive for HIV infection

          -  Prior allogeneic stem cell or solid organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO41596 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter Mac Callum Cancer Center</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center - PPDS</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System - Clinical Trials Center Pharmacy</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>VU Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radboud Universitair Medisch Centrum; Department Hematology</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 HP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com).
Further details on Roche's criteria for eligible studies are available here: https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

